Letter to the Editor
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Cardiol. Nov 26, 2024; 16(11): 665-668
Published online Nov 26, 2024. doi: 10.4330/wjc.v16.i11.665
Effects of sodium-dependent glucose transporter 2 inhibitors in patients with type 2 diabetes mellitus and asymptomatic heart failure
Mohamed H Laimoud, Ismail R Raslan
Mohamed H Laimoud, Department of Cardiovascular Critical Care, Prince Sultan Cardiac Center, Riyadh 12611, Saudi Arabia
Mohamed H Laimoud, Critical Care Medicine, Cairo University, Cairo 12613, Egypt
Ismail R Raslan, Department of Cardiac Sciences, King Saud University, Riyadh 11362, Saudi Arabia
Ismail R Raslan, Department of Adult Cardiology, Prince Sultan Cardiac Center, Riyadh 12611, Saudi Arabia
Author contributions: Laimoud MH and Raslan IR contributed equally to this editorial manuscript and approved the final version.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Mohamed H Laimoud, MD, PhD, Associate Professor, Department of Cardiovascular Critical Care, Prince Sultan Cardiac Center, Makkah Al Mukarramah Br Road, As Sulimaniyah, Riyadh, Riyadh 12611, Saudi Arabia. m.laimoud@cu.edu.eg
Received: August 24, 2024
Revised: October 14, 2024
Accepted: October 23, 2024
Published online: November 26, 2024
Processing time: 67 Days and 10.7 Hours
Core Tip

Core Tip: Grubić Rotkvić et al published an observational study on the use of sodium-dependent glucose transporter 2 inhibitors (SGLT2i) in patients with type 2 diabetes mellitus and asymptomatic heart failure. Their findings included reduced cardiac load and improved cardiovascular performance related to the use of SGLT2i. This suggests that SGLT2i are not merely glucose-lowering drugs; they are integral to the broader cardiovascular management in patients with type 2 diabetes mellitus.